Vimarsana
Biggest News Aggregation in the World

Session Display Date News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Session Display Date. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Session Display Date Today - Breaking & Trending Today

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - Vimarsana News

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Published: September 27, 2023

27.09.2023 - Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T Cells Demonstration of Dagger Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune ... Seite 1

Source: wallstreet-online.de
Related Topics:
San DiegoUnited StatesZachary RobertsElvin LauronResearch DevelopmentAllogene Therapeutics IncDemonstration Of Dagger Technology To EngineerSociety For Immunotherapy Of CancerTargeted TechnologiesEnhance EngraftmentDagger TechnologySelectively EliminateAllo Reactive Host Immune CellsCloak TechnologyEngineer Allogeneic CellsHost Immune SystemCandidate Targeting ClaudinPancreatic CancersAnnual Meeting NovemberExecutive Vice PresidentChief MedicalCells ExpressingSession Display DateExhibit HallsImmune Evasive Allogeneic
Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting - Vimarsana News

Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

Published: May 31, 2023

/PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the...

Source: prnewswire.com
Related Topics:
United StatesSouth San FranciscoDeyaa AdibPrnewswire Triumvira ImmunologicsDavid SchullBenjaminl SchlechterBenjamin SchlechterIgnacio Guerrero RosTriumvira ImmunologicsDana Farber Cancer InstituteHarvard Medical SchoolAmerican SocietyTriumvira Immunologics IncSociety Of Clinical OncologyAnnual MeetingSenior PhysicianGastrointestinal OncologyChief Medical OfficerPrincipal InvestigatorInvestigating SafetyRefractory Solid TumorsAttending PhysicianMedical OncologyDana Farber CancerDevelopmental Therapeutics
Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting - Vimarsana News

Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Published: May 25, 2023

HOUSTON--(BUSINESS WIRE)--May 25, 2023--

Source: wsiltv.com
Related Topics:
United StatesImran AlibhaiSara ManningApostoliam TsimberidouAmerican Society Of Clinical OncologyTvardi Therapeutics IncAmerican SocietyClinical OncologyPoster Discussion SessionTargeted AgentsSession Display DateBoard NumberDiscussion Session DateTvardi InvestorBusiness Wire
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Published: May 25, 2023

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

Source: prnewswire.com
Related Topics:
United StatesLee CranmerGopa IyerClinical Research Excluding TrialsMemorial Sloan Kettering Cancer CenterFred Hutch Cancer CenterAadi Bioscience IncPrnewswire Aadi Bioscience IncPoster SessionMolecularly Targeted AgentsMemorial Sloan Kettering CancerSession Display DateBoard NumberDiscussion Session DateClinical Research ExcludingPoster Discussion SessionFred Hutch CancerAadi BioscienceHealth Care Amp HospitalsMedical Pharmaceuticals Pharmaceuticals Trade Show NewsClinical Trials Amp Medical Discoveries
Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting - Vimarsana News

Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting

Published: May 16, 2023

/PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the...

Source: prnewswire.com
Related Topics:
United StatesSouth San FranciscoPrnewswire Triumvira ImmunologicsIgnacio Guerrero RosBenjaminl SchlechterTriumvira ImmunologicsDeyaa AdibDana Farber Cancer InstituteHarvard Medical SchoolAmerican SocietyTriumvira Immunologics IncSociety Of Clinical OncologyAnnual MeetingSenior PhysicianGastrointestinal OncologyChief Medical OfficerInvestigating SafetyRefractory Solid TumorsAttending PhysicianMedical OncologyDana Farber CancerDevelopmental TherapeuticsSession Display DateDiscussion Session DateAntigen Coupler